NEW AWARD FOR UBLITUXIMAB-XIIY 150MG/6ML INJECTION (ANTI-CD20 ANTIBODIES WITH TG THERAPEUTICS. PERIOD OF PERFORMANCE JUNE 17, 2024 - JUNE 16, 2025 WITH FOUR ONE-YEAR OPTIONS.

Statistical observations derived from public procurement data. Patterns identified do not constitute findings, accusations, or allegations of wrongdoing. All analysis is based on publicly available records and requires independent verification before any action is taken. This is not legal advice. Terms of Service